THC ~2.5%
Cannabis flower containing THC \~2.5%
THC · delta 9-tetrahydrocannabinol · marijuanaLoading study record…
Loading study record…
This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-03-16
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
In this double-blind, randomized, crossover trial, subjects will treat 4 separate migraine attacks with 4 different treatments. Inhaled cannabis will be administered using a portable system. Subjects will self-administer inhaled cannabis as early as possible in the course of a migraine, taking 4 puffs of 1) THC 2.5%, 2) THC 5%, 3) THC 10%, or 4) placebo. Patients will treat each of the 4 distinct migraine attacks with a different cannabis sample. Outcomes measured will include pain freedom, most bothersome symptom (MBS), and pain relief as well as presence or absence of photophobia, phonophobia, and nausea at 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 24 hours, and 48 hours.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Cannabis flower containing THC \~2.5%
THC · delta 9-tetrahydrocannabinol · marijuanaCannabis flower containing THC \~5%
THC · delta 9-tetrahydrocannabinol · marijuanaCannabis flower containing THC \~5%
THC · delta 9-tetrahydrocannabinol · marijuanaCannabis flower from which the THC and CBD have been extracted
Placebo · ShamEligibility
primary outcomes
Time frame: 2 Hours Post-Treatment
Dichotomous outcome of pain freedom defined as reduction from moderate/severe pain to no pain
secondary outcomes
Time frame: 2 Hours Post-Treatment
Dichotomous outcome of resolution of most bothersome symptom (of photophobia, phonophobia, or nausea) selected at the beginning of the migraine prior to cannabis administration
Time frame: 2 Hours Post-Treatment
Dichotomous outcome of pain reduction defined as reduction from moderate/severe pain to mild/no pain
other outcomes
Time frame: 15 minutes, 30 minutes, 1 hour, 1.5 hours, 4 hours, 24 hours, 48 hours
Dichotomous outcome of reduction from moderate/severe to no pain
Time frame: 15 minutes, 30 minutes, 1 hour, 1.5 hours, 4 hours, 24 hours, 48 hours
Dichotomous outcome of resolution of MBS (of photophobia, phonophobia, or nausea) selected at the beginning of the migraine prior to cannabis administration
Time frame: 15 minutes, 30 minutes, 1 hour, 1.5 hours, 4 hours, 24 hours, 48 hours
Dichotomous outcome of reduction from moderate/severe to mild/no pain
Time frame: 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 24 hours, 48 hours
Dichotomous outcome of resolution of photophobia
Time frame: 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 24 hours, 48 hours
Dichotomous outcome of resolution of phonophobia
Time frame: 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours, 24 hours, 48 hours
Dichotomous outcome of resolution of nausea
Time frame: At any time over 48 hours
Dichotomous outcome of whether patient vomited during this migraine attack
Time frame: At any time over 48 hours
Dichotomous outcome of use of rescue medication
Time frame: 24 hours and 48 hours
Dichotomous outcome of absence of headache pain at 2 hours after dose, with no use of rescue medication and no recurrence of headache pain
Time frame: 24 hours and 48 hours
Dichotomous outcome of absence of MBS at 2 hours after dose, with no use of rescue medication and no recurrence of MBS
Publications
No exact PMID-linked public article is currently readable locally.